NPPB and type 2 diabetes mellitus: In another study of 35 patients with T2DM and HFrEF who were randomized to empagliflozin vs. placebo, patients who received empagliflozin demonstrated significantly decreased ANP and BNP levels compared to baseline at all times [162].